Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
- Tachycardia Atrial
- Atrial Fibrillation
- Atrial Flutter With Rapid Ventricular Response
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Wake Forest University Health Sciences
- Enrolment target
- 153
- Started
- 7 October 2024
- Main results due
- December 2026
- Study sites
- 1
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age \> 18 years or older * Able to provide informed consent * Primary diagnosis AFF RVR greater than or equal to 120 bpm * Diltiazem as rate control agent * English speaking Exclusion Criteria: * Hemodynamically unstable patients (SBP \<90, MAP \<65) * Impaired consciousness * End stage renal disease on hemodialysis or peritoneal dialysis * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis * Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response * Acute myocardial infarction * Pregnancy defined as a positive urine HCG (human chorionic gonadotropin) * Contraindications to magnesium sulfate (including myasthenia gravis) * Allergy or sensitivity to any study drugs * Previously enrolled in this trial during a different patient encounter * Withdrew from study
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Study sites(1)
Advocate Christ Medical Center Emergency Department (ACMC ED)
Oak Lawn, Illinois, United States
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06376916. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me